Phosphoproteome Analysis of Trastuzumab Resistant Breast Cancer Cells

摘要

Targeted therapy represents a novel regimen of caner management, which is exemplified by a new generation of anti-kinase drugs. These drugs specifically inhibit a kinase or multiple kinases that play critical roles in cancer development and advance. While the advantages of targeted therapy are obvious, such therapy often relapses and results in drug resistance for advanced cancers. Unraveling anti-kinase drug resistance mechanisms would facilitate novel drug development and in turn better understanding of drug cytotoxicity. The MS-based phosphoproteomic technologies provide novel approaches to the identification of phosphosignatures unique to a specific type or subtype of cancer and drug responsive biomarkers for personalized therapy. In this study, the phosphoproteome of trastuzumab resistant human breast cancer JIMT-1 cells was analyzed using improved titanium dioxide (TiO_(2)) phosphopeptide enrichment and tandem mass spectrometry. Significant phosphoproteins related to this type of disease were identified.